Abstract:Objective: To determine the impact of major disease epidemics on pharmaceutical manufacturing firms' Research & Development (R&D) investments and economic consequences. Methods: The sample consists of 1 582 firm-year observations from 2009 to 2022 in China, of which, 26.6% of pharmaceutical companies are involved in the diagnosis and treatment of prevalent diseases. Linear models using R&D investments, patent applications, operating performances and stock returns as dependent variables are constructed separately to examine the response of pharmaceutical companies to disease epidemics and the resulting economic consequences. Results: The prevalence of five major diseases led to a 17.5% increase in the amount of R&D investment and an 87.8% rise in the ratio of R&D investment to total assets by disease-related pharmaceutical companies, compared to unrelated pharmaceutical companies. Further evidence indicated that the patent applications for disease-related firms increased by 44.3% relative to unrelated firms after the epidemics. Though the impacts of the epidemics on firms' operating performances were insignificant in the short term, a major disease epidemic was associated with an increase in stock returns of 67.4% and 44.6%, respectively, as measured by the capital asset pricing model and Fama-French five-factor model. Additional analysis revealed that the impacts of the epidemics on R&D investments and patent applications were more pronounced for non-state-owned enterprises than state-owned enterprises. Conclusions: This study demonstrates that disease-related pharmaceutical firms respond to the disease epidemics through increasing R&D investment. More patent applications and higher market value are the main gains from the firms' increased investments in R&D following the epidemic, rather than the improvements of short-term operating performances.

Pandemic and bank lending: Evidence from the 2009 H1N1 pandemic

Emergency Surveillance of Influenza During 2009 in the Chinese City of Qingdao

Domestic lending and the pandemic: How does banks’ exposure to COVID-19 abroad affect their lending in the United States?

Impact of H1N1, H7N9, ASFV, dengue virus and COVID-19 on pharmaceutical manufacturing firms' R&D investments and economic consequences: Evidence from China

The COVID-19 pandemic, consumption and sovereign credit risk: Cross-country evidence

Impact of the 2009 H1n1 Pandemic on Age-Specific Epidemic Curves of Other Respiratory Viruses: A Comparison of Pre-Pandemic, Pandemic and Post-Pandemic Periods in A Subtropical City

The Economic Impact of Pandemics: Real and Financial Transmission Channels

Pandemic Bonds Issued by the Chinese Government Supported Post-Disaster Recovery from COVID-19 Pandemic

COVID‐19 and credit risk variation across banks: International insights

Sovereign debt responses to the COVID-19 pandemic

SMEs’ line of credit under the COVID-19: evidence from China

Influence of institutional differences on trade credit use during pandemics

Genomic Signature and Mutation Trend Analysis of Pandemic (H1N1) 2009 Influenza A Virus

The First Pandemic of the 21st Century:2009 A (H1N1) Influenza

Financial Network Connectedness and Systemic Risk During the COVID-19 Pandemic

Transmission Dynamics, Border Entry Screening, and School Holidays During the 2009 Influenza A (H1N1) Pandemic, China

Monetary policy transmission under pandemic uncertainty: Effect on banks' risk and capital adjustments

The Impact of SARS Epidemic on Firm Investment: Evidence from Listed Firms in China

Debt rollover risk, credit default swap spread and stock returns: Evidence from the COVID-19 crisis

2009 Pandemic Characteristics and Controlling Experiences of Influenza H1N1 Virus 1 Year after the Inception in Hangzhou, China.

Bank liquidity hoarding during the COVID-19 pandemic